This Title All WIREs
How to cite this WIREs title:
Impact Factor: 9.957

The powerful world of antisense oligonucleotides: From bench to bedside

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs have transformed them into true approved and commercialized drugs. ASOs target both DNA and RNA, including pre‐mRNA, mRNA, and ncRDA, based on sequence complementary. They are designed to be specific for each identified molecular and genetic alteration to restore a normal, physiological situation. Thus, the characterization of the underpinning mechanisms and alterations that sustain pathology is critical for accurate ASO‐design. ASOs can be used to cure both rare and common diseases, such as orphan genetic alterations and cancer. Through pioneering examples, this review shows the versatility of the mechanisms of action that provide ASOs with the potential capacity to achieve custom treatment, revolutionizing personalized medicine. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Interactions with Proteins and Other Molecules > Small Molecule–RNA Interactions
Chemical structure of first, second, and third generation ASOs, compared to DNA and RNA structures, followed with examples of FDA‐approved drugs. 2′‐MOE, 2′‐O‐methoxyethyl; 2′‐OME, 2‐O‐methyl; ASOs, antisense oligonucleotides; DNA, deoxyribonucleotidic acid; LNA, locked nucleic acid; MF, morpholino phosphorodiamidate; PMO, phosphorodiamidate morpholino oligomer; PNA, peptide nucleic acid; PS, phosphorothioate; RNA, ribonucleotidic acid
[ Normal View | Magnified View ]
Inhibition of TYRP1 miRNA sponge activity as a therapeutic strategy
[ Normal View | Magnified View ]
Schematic representation of multiple therapeutic options using ASOs. ASOs, antisense oligonucleotides
[ Normal View | Magnified View ]
Timeline of ASO drug development and approval. ASO, antisense oligonucleotide; hATTR, polyneuropathy of hereditary transthyretin‐mediated amyloidosis; NMD, nonsense‐mediated decay; SMA, spinal muscular amyotrophy
[ Normal View | Magnified View ]

Browse by Topic

RNA Interactions with Proteins and Other Molecules > Small Molecule–RNA Interactions
RNA in Disease and Development > RNA in Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts